中资参股癌症诊断科技公司Radiopharm首秀破发

澳华财经在线：首页 > 澳洲财经 > 产经动态

2021-11-26 06:36:00 来源：《澳华财经在线》 编辑：Anna 文章类型：原创

ACB News《澳华财经在线》11月26日讯周四Radiopharm治疗诊断科技（ASX:RAD）澳交所首秀破发，收盘价较发行价下挫33%。

Radiopharm IPO以每股60澳分发行价，共计募集5000万澳元，公司估值达1.52亿澳元。然而周四开盘不久其股价开始震荡下滑，截止收盘跌至40澳分每股。

Radiopharm是早期阶段公司，目前并无技术许可协议安排或产品销售收入。公司正在开发用于癌症诊断和治疗的放射性药物产品平台。

公告显示，上海的和迈医药科技有限公司为Radiopharm第二大股东，持股8.33%。其他主要股东包括机构投资者Thorney科技和Frazis资本合伙人。

ASX上市公司Imugene(ASX:IMU)的CEO及多位投资人也是Radiopharm支持者，其他股东还包括CHAMP Venture的Su-Ming Wong、时尚设计师科莱特·迪尼根等。

3中资参股癌症诊断2.jpg

( 图片来源：《澳华财经在线》)

据Refinitiv数据，今年以来澳交所挂牌新股数量达121家，为2007年（136家）以来最多的一年，但并非所有的新股都是一帆风顺。

据澳洲金融评论报，Tamim资产管理公司澳股部主管 Ron Shamgar评论称，“在我看来，似乎大部分破发的IPO都遇到了短线投资者，而非真正对他们产品感兴趣的投资人。”

过去一年，澳交所首日破发的IPO不在少数：一周前上市的生物医药公司 Tissue Repair(TRP) 首秀下挫40%；

去年12月上市的YouFoodz(ASX：YFZ)首秀下挫30%，今年2月上市的Little Green Pharma(ASX：LGP)首日下跌33%。

【小编贴士：】手机端阅读时，点击文章页面左上Logo即可返回首页阅读。祝读者朋友天天健康、开心！工作投资顺利。

免责声明：本文为财经观察评论，不构成任何投资建议，交易操作或投资决定请询问专业人士。

( 郑重声明：ACB News《澳华财经在线》对标注为原创的文章保留全部著作权限，任何形式转载请标注出处。)

Tags: RAD IPO 医药股癌症治疗诊断科技中资股价 Radiopharm

相关阅读

: 招聘｜昆士兰州政府贸易投资机构深圳招聘助理办公室经理（LES 5.1）

Job VacancyTIQ ChinaTrade and Investment Queensland China is seeking an Assistant Operations Manager to join our S...

: China-Australia service trade, a sophisticated symphony

When the 2025 China International Fair for Trade in Services (CIFTIS) opens in Beijing on September 10, Australia, the guest country of honor this year, will bring its largest-ever delegation to the event.

: Bowen Coking Coal (ASX: BCB) Hits FY25 Output Target Early, Seeks Funding in Trading Halt

While The company confirmed it had achieved its full-year FY25 run-of-mine (ROM) coal production and sales guidance , Bowen’s share price declined sharply prior to the trading halt, closing at A$0.096 on 23June, with the company’s market capitalisation falling at about A$10 million — a sharp contrast to the hundreds of millions it was valued at during the COVID-era peak.

: Solstice Minerals (ASX: SLS) Receives Paradice Commitment for $2.13M Placement, Completion Expected 20 June

Solstice Minerals Limited (ASX: SLS) announced on Monday that it has received a firm commitment from institutional investor Paradice Investment Management for a $2.13 million strategic placement. Upon completion, Paradice will become the company’s largest shareholder, holding a 9.90% stake.

: Solstice Minerals（ASX: SLS）获Paradice认购承诺拟于6月20日完成213万澳元定向增发

今日发布增发消息的 Solstice Minerals（ASX: SLS）股价早盘创出上市以来新高0.30澳元。西澳黄金矿产勘探公司 Solstice Minerals Limited（ASX: SLS）周一宣布，公司已收到来自知名机构投资者 Paradice Investment Management 的认购承诺，拟通过战略定向增发方式融资约 213万澳元。交易完成后，Paradice 将成为公司第一大股东，持股比例达 9.90%。

: Australian Stock Market Hits Record High in Wednesday Morning Trade – ASX 200 Index Touches 8,639 Points Amid Broad-Based Market Momentum

In an exclusive report published on Monday titled “[U.S. Market Watch] Wall Street Rises at Start of June, Dow Could Head Towards 45,000 – Further Signals Needed to Confirm Trend”, we noted that despite a late-week pullback, the overall trend of the Australian equity market remained upward.

: Barton Gold Completes A$3M Premium Placement, Launches High-Grade Silver Drilling at Tolmer

Barton Gold Holdings Limited (ASX: BGD) has successfully completed a A$3 million premium placement to Australian precious metals-focused investors, strengthening its balance sheet to support ongoing drilling at the flagship Tunkillia Gold Project and accelerating exploration at its high-grade Tolmer silver discovery.

: ImpediMed (ASX: IPD) Delivers Record Q3 Results; Shares Rebound Last Week with Increasing Trading Volume

ImpediMed Limited (ASX: IPD) has reported record financial results for Q3 FY25, with revenue reaching A$3.4 million (+28% YoY), cash receipts at A$4.1 million, and ARR rising to A$13.7 million (+27% YoY). Total Contracted Value (TCV) hit A$4.9 million, up 53% from the previous quarter.

免责声明：本网站信息仅供一般参考，不构成投资或财务建议。虽力求准确与完整，但不保证信息的准确性、完整性或时效性。投资有风险，决策前请咨询专业独立顾问。使用本网站即视为接受本免责声明。